Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 8/20 | 0.50 |
| ▸ | CNR2 | P34972 | 5/20 | 0.47 |
| ▸ | DRD4 | P21917 | 4/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | DRD3 | P35462 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14228800 | 1.00 | SLC6A2 (0.50) | SLC6A2CNR2DRD4CYP1A2CYP3A4 | |
| SCHEMBL14203046 | 1.00 | SLC6A2 (0.50) | SLC6A2CNR2DRD4CYP1A2CYP3A4 | |
| SCHEMBL5042305 | 0.92 | SLC6A2 (0.59) | SLC6A2CNR2DRD4CYP1A2CYP3A4 | |
| SCHEMBL14203009 | 0.92 | SLC6A2 (0.59) | SLC6A2CNR2DRD4CYP1A2CYP3A4 | |
| SCHEMBL14203004 | 0.90 | SLC6A2 (0.59) | SLC6A2CNR2DRD4CYP1A2CYP3A4 | |
| SCHEMBL14202973 | 0.90 | SLC6A2 (0.59) | SLC6A2CNR2DRD4CYP1A2CYP3A4 | |
| SCHEMBL5046485 | 0.90 | SLC6A2 (0.59) | SLC6A2CNR2DRD4CYP1A2CYP3A4 | |
| SCHEMBL8284229 | 0.90 | SLC6A2 (0.59) | SLC6A2CNR2DRD4CYP1A2CYP3A4 | |
| SCHEMBL14580282 | 0.85 | SLC6A2 (0.46) | SLC6A2CNR2DRD4CYP1A2CYP3A4 | |
| SCHEMBL14203075 | 0.85 | SLC6A2 (0.46) | SLC6A2CNR2DRD4CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7354920-B2 | Aryl and heteroaryl morpholine derivatives | ELI LILLY AND COMPANY (US) | 2008-04-08 | — | — | US | disclosed |
| US-20070032554-A1 | Treatment of stuttering and other communication disorders with norepinephrine reuptake inhibitors | ELILILLY AND COMPANY A CORPORATION | 2007-02-08 | — | — | US | disclosed |
| US-20070015786-A1 | Treatment of hot flashes, impulse control disorders and personality change due to a general medical condition | ELI LILY AND COMPANY (US) | 2007-01-18 | — | — | US | disclosed |
| US-20070002232-A1 | Optical compensation film, polarizing plate and liquid crystal display device | FUJI PHOTO FILM CO., LTD. (JP) | 2007-01-04 | — | — | US | disclosed |
| EP-1729754-A2 | SELECTIVE NOREPINEPHRINE REUPTAKE INHIBITORS FOR THE TREATMENT OF HOT FLASHES, IMPULSE CONTROL DISORDERS AND PERSONALITY CHANGE DUE TO A GENERAL MEDICAL CONDITION | ELI LILLY AND COMPANY (US) | 2006-12-13 | — | — | EP | disclosed |
| US-20060241188-A1 | Treatment of pervasive developemental disorders with norepinephrine reuptake inhibitors | ELILILLY AND COMPANY (US) | 2006-10-26 | — | — | US | disclosed |
| EP-1660064-A2 | TREATMENT OF LEARNING DISABILITIES AND MOTOR SKILLS DISORDER WITH NOREPINEPHRINE REUPTAKE INHIBITORS | ELI LILLY AND COMPANY (US) | 2006-05-31 | — | — | EP | disclosed |
| EP-1660065-A2 | TREATMENT OF PERVASIVE DEVELOPMENTAL DISORDERS WITH NOREPINEPHRINE REUPTAKE INHIBITORS | ELI LILLY AND COMPANY (US) | 2006-05-31 | — | — | EP | disclosed |
| US-20060003998-A1 | Aryl and heteroaryl morpholine derivatives | ELI LILLY AND COMPANY (IN) | 2006-01-05 | — | — | US | disclosed |
| WO-2005060949-A2 | SELECTIVE NOREPINEPHRINE REUPTAKE INHIBITORS FOR THE TREATMENT OF HOT FLASHES, IMPULSE CONTROL DISORDERS AND PERSONALITY CHANGE DUE TO A GENERAL MEDICAL CONDITION | ELI LILLY AND COMPANY (US) | 2005-07-07 | — | — | WO | disclosed |
| WO-2005053663-A2 | NOREPINEPHRINE REUPTAKE INHIBITORS USEFUL FOR TREATMENT OF COGNITIVE FAILURE | ELI LILLY AND COMPANY (US) | 2005-06-16 | — | — | WO | disclosed |
| EP-1534694-A1 | ARYL AND HETEROARYL MORPHOLINE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2005-06-01 | — | — | EP | disclosed |
| WO-2005020976-A2 | TREATMENT OF PERVASIVE DEVELOPMENTAL DISORDERS WITH NOREPINEPHRINE REUPTAKE INHIBITORS | ELI LILLY AND COMPANY (US) | 2005-03-10 | — | — | WO | disclosed |
| WO-2005020975-A2 | TREATMENT OF LEARNING DISABILITIES AND MOTOR SKILLS DISORDER WITH NOREPINEPHRINE REUPTAKE INHIBITORS | ELI LILLY AND COMPANY (US) | 2005-03-10 | — | — | WO | disclosed |
| WO-2004018441-A1 | ARYL AND HETEROARYL MORPHOLINE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2004-03-04 | — | — | WO | disclosed |
| US-6503593-B2 | Such as DVD, comprising a polymer substrate and a radiation-cured coating provided by curing a composition of pH greater than or equal to three and comprising at least one acrylate monomer; low jitter under given heat and humidity | DSM N.V. (NL) | 2003-01-07 | — | — | US | disclosed |
| EP-1185984-A2 | RADIATION-CURABLE COATINGS FOR OPTICAL DISCS AND OPTICAL DISCS INCORPORATING SUCH COATINGS | DSM N.V. (NL) | 2002-03-13 | — | — | EP | disclosed |
| WO-2001026107-A2 | RADIATION-CURABLE COATINGS FOR OPTICAL DISCS AND OPTICAL DISCS INCORPORATING SUCH COATINGS | DSM N.V. (NL) | 2001-04-12 | — | — | WO | disclosed |
| US-6214433-B1 | FOR COMPACT DISKS, DIGITAL VIDEO DISKS(DVDS), CD-ROM; PERFORMANCE | DSM N.V. (NL) | 2001-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060003998-A1 | Aryl and heteroaryl morpholine derivatives | ADRA2C, HTR2C, ADRB1 | SLC6A2 19/4885CNR2 76/4885DRD4 36/4885 |
| US-20060241188-A1 | Treatment of pervasive developemental disorders with norepinephrine reuptake inhibitors | SLC6A2, SLC6A3, SLC6A4 | SLC6A2 1/4885CNR2 466/4885DRD4 6/4885 |
| US-20070032554-A1 | Treatment of stuttering and other communication disorders with norepinephrine reuptake inhibitors | SLC6A2, SLC6A4, SLC6A3 | SLC6A2 1/4885CNR2 1137/4885DRD4 52/4885 |
| US-20070015786-A1 | Treatment of hot flashes, impulse control disorders and personality change due to a general medical condition | SLC6A2, SLC6A4, HTR5A | SLC6A2 1/4885CNR2 247/4885DRD4 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.